Abstract Details

Title Infection Rates in Rechargeable Cell Implantable Pulse Generators Compared to Primary Cell Implantable Pulse Generators in Patients Undergoing Deep Brain Stimulation Surgery

Topic Movement Disorders

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-019

Objective To compare the infection rates of patients with rechargeable cell (RC) implantable pulse generators (IPGs) to those with primary cell (PC) IPGs.

Background RC IPGs extend battery longevity compared to PC IPGs in deep brain stimulation (DBS) procedures. With each subsequent battery replacement procedure, there is a heightened susceptibility to post-operative infections. We conducted this study to evaluate the infection rates between patients with RC IPGs and patients with PC IPGs.

Design/Methods We completed a retrospective chart review of all patients who underwent DBS procedures for any indication from 2016 to 2022 at our institution. We included all phases of DBS surgery, including electrode implantation, IPG implantation, IPG replacement, and hardware revisions and removals.

Results 637 patients underwent 1,521 DBS procedures during the study period. The overall infection rate was 2.56% (n=39/1521) per procedure and 5.02% (n=32/637) per patient. For PC IPGs, the infection rate was 2.69% (n=23/855) per procedure and 4.68% (n=21/449) per PC patient. Infections occurred after PC replacement at the rate of 2.03% (n=13/639). For RC IPGs, the infection rate was 4.55% (n=9/198) per procedure and 3.70% (n=6/162) per RC patient. There were no infections following the 4 RC replacements. There was no difference in infection rates between RC and PC IPGs per procedure (p=0.17) or per patient (p=0.59) after initial IPG implantation. However, one-third of infections (n=13/39) occurred after replacement of PC IPGs, while there were no infections after replacement of RC IPGs during the six-year study duration.

Conclusions In this single-center study, patients with RC IPGs had a reduced infection rate compared to patients with PC IPGs from IPG replacement. This difference is likely due to a less frequent need for IPG replacement with RC IPGs.

Authors/Disclosures
Gabrielle A. Walsh, MD PRESENTER	Ms. Walsh has nothing to disclose.
Deepal P. Shah-Zamora, MD (Atrium Health Wake Forest Baptist)	Dr. Shah-Zamora has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Winthrop Industrie. The institution of Dr. Shah-Zamora has received research support from CereGate Inc. The institution of Dr. Shah-Zamora has received research support from Amneal. The institution of Dr. Shah-Zamora has received research support from AbbVie .
Adrian Laxton	No disclosure on file
Stephen B. Tatter, MD (Wake Forest Univ School of Medicine)	The institution of Dr. Tatter has received research support from Monteris Medical, Inc. The institution of Dr. Tatter has received research support from Arbor Pharmaceuticals. Dr. Tatter has received intellectual property interests from a discovery or technology relating to health care.
Mustafa S. Siddiqui, MD, FAAN	Dr. Siddiqui has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific Neuromodulation. Dr. Siddiqui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Siddiqui has received research support from Boston Scientific Neuromodulation. The institution of Dr. Siddiqui has received research support from Abbvie. The institution of Dr. Siddiqui has received research support from National Institute of Health .

��ɫ��

��ɫ��